Posted by Michael Wonder on 03 Feb 2016
Tagrisso (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
3 February 2016 - Tagrisso is the first new medicine to be approved under the European Commission’s expedited process.
For more details, go to: https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-lung-cancer-03022016.html
